Sucralose Linked to Reduced Cancer Treatment Effectiveness, New Research Suggests
A widely used artificial sweetener, sucralose, may hinder the effectiveness of cancer treatments, particularly for patients with melanoma and non-small cell lung cancer, according to a new study from the University of Pittsburgh and UPMC Hillman Cancer Centre. The research raises concerns about the potential impact of common sugar substitutes on cancer survival rates and immune response.
A popular choice for individuals managing weight or blood sugar, sucralose appears to disrupt the body’s ability to respond to therapies, prompting scientists to explore potential countermeasures.
Sucralose and Cancer Survival Rates
The study revealed that cancer patients who regularly consume sucralose exhibited lower survival rates compared to those with minimal intake of the artificial sweetener. Researchers specifically focused on patients undergoing treatment for melanoma and non-small cell lung cancer, observing a correlation between sucralose consumption and diminished treatment outcomes.
According to the research, the negative effects stem from the sweetener’s impact on the body’s internal ecosystem.
Gut Bacteria Disruption and Arginine Depletion
Testing conducted on mice revealed that sucralose alters the composition of gut bacteria, leading to an increase in bacteria that degrade arginine, an essential amino acid. This degradation results in reduced arginine levels in the blood, tumor fluid, and stool.
“When arginine levels were depleted due to sucralose-driven shifts in the microbiome, T cells couldn’t function properly,” one expert explained. “As a result, immunotherapy wasn’t as effective in mice that were fed sucralose.”
Arginine Supplementation Offers Potential Countermeasure
The research team identified a potential pathway to mitigate the adverse effects of sucralose. Supplementation with arginine appeared to counteract the sweetener’s negative impact on immunotherapy treatments in the animal models.
Researchers believe this approach warrants further investigation through clinical trials to determine its applicability to human patients.
Balancing Dietary Realities with Cancer Treatment
Doctor Abby Overacre, assistant professor in the Department of Immunology at the University of Pittsburgh and UPMC Hillman, emphasized the importance of practical solutions for cancer patients. “It’s easy to say, ‘Stop drinking diet soda,’ but when patients are being treated for cancer, they are already dealing with enough, so asking them to drastically alter their diet may not be realistic,” she said.
“We need to meet patients where they are. That’s why it’s so exciting that arginine supplementation could be a simple approach to counteract the negative effects of sucralose on immunotherapy,” Dr. Overacre added. This finding suggests a potential strategy to support cancer treatment without requiring significant and potentially burdensome dietary changes.
